220 related articles for article (PubMed ID: 12608532)
1. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.
Woo JS; Lee CH; Shim CK; Hwang SJ
Pharm Res; 2003 Jan; 20(1):24-30. PubMed ID: 12608532
[TBL] [Abstract][Full Text] [Related]
2. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
Varma MV; Panchagnula R
Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
5. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.
Yang S; Gursoy RN; Lambert G; Benita S
Pharm Res; 2004 Feb; 21(2):261-70. PubMed ID: 15032307
[TBL] [Abstract][Full Text] [Related]
6. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
van Asperen J; van Tellingen O; Sparreboom A; Schinkel AH; Borst P; Nooijen WJ; Beijnen JH
Br J Cancer; 1997; 76(9):1181-3. PubMed ID: 9365166
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of paclitaxel transport and cytotoxicity by 7,3',4'-trimethoxyflavone, a P-glycoprotein inhibitor.
Jeong JM; Choi CH
J Pharm Pharm Sci; 2007; 10(4):547-53. PubMed ID: 18261374
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
Mo R; Jin X; Li N; Ju C; Sun M; Zhang C; Ping Q
Biomaterials; 2011 Jul; 32(20):4609-20. PubMed ID: 21440934
[TBL] [Abstract][Full Text] [Related]
9. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats.
Choi JS; Choi HK; Shin SC
Int J Pharm; 2004 May; 275(1-2):165-70. PubMed ID: 15081147
[TBL] [Abstract][Full Text] [Related]
10. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats.
Choi JS; Shin SC
Int J Pharm; 2005 Mar; 292(1-2):149-56. PubMed ID: 15725561
[TBL] [Abstract][Full Text] [Related]
11. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Lee CK; Choi JS
Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
[TBL] [Abstract][Full Text] [Related]
12. The ethanol metabolite acetaldehyde increases paracellular drug permeability in vitro and oral bioavailability in vivo.
Fisher SJ; Swaan PW; Eddington ND
J Pharmacol Exp Ther; 2010 Jan; 332(1):326-33. PubMed ID: 19820208
[TBL] [Abstract][Full Text] [Related]
13. Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats.
Cai Q; Deng X; Li Z; An D; Shen T; Zhong M
Drug Deliv; 2016; 23(1):147-53. PubMed ID: 24786483
[TBL] [Abstract][Full Text] [Related]
14. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
Choi JS; Piao YJ; Kang KW
Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
[TBL] [Abstract][Full Text] [Related]
15. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats.
Choi DH; Li C; Choi JS
Eur J Drug Metab Pharmacokinet; 2009; 34(3-4):163-8. PubMed ID: 20166433
[TBL] [Abstract][Full Text] [Related]
16. Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo.
Yang LQ; Wang B; Gan H; Fu ST; Zhu XX; Wu ZN; Zhan DW; Gu RL; Dou GF; Meng ZY
Biopharm Drug Dispos; 2012 Nov; 33(8):425-36. PubMed ID: 22898996
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Choi DH; Chung JH; Choi JS
Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601
[TBL] [Abstract][Full Text] [Related]
18. The effect of verapamil on the pharmacokinetics of paclitaxel in rats.
Choi JS; Li X
Eur J Pharm Sci; 2005 Jan; 24(1):95-100. PubMed ID: 15626582
[TBL] [Abstract][Full Text] [Related]
19. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
Park JH; Park JH; Hur HJ; Woo JS; Lee HJ
Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604
[TBL] [Abstract][Full Text] [Related]
20. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Alsenz J; Steffen H; Alex R
Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
